ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.545
      -0.28%
      Bitcoin
      65,159.79
      0.03%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Deciphera Pharmaceuticals Inc (DCPH)

      7. Deciphera Pharmaceuticals Inc (DCPH) News

      DCPH

      Deciphera Pharmaceuticals (DCPH)

      Deciphera Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:DCPH
      DateTimeSourceHeadlineSymbolCompany
      11/07/20237:00AMBusiness WireDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      10/31/20234:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      10/31/20234:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      10/30/20237:11AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      10/30/20237:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      10/30/20237:01AMBusiness WireDeciphera Pharmaceuticals Announces Third Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      10/30/20237:00AMBusiness WireDeciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCTNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      09/29/20239:00AMPR Newswire (US)Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) TreatmentNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      09/29/20239:00AMPR Newswire (Canada)Medison Pharma Announces Public Formulary Listing of QINLOCK® (ripretinib) in Canadian Provinces: Ontario and Quebec for Advanced Gastrointestinal Stromal Tumor (GIST) TreatmentNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      09/19/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      09/15/20235:00PMBusiness WireDeciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      09/05/20234:15PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      08/18/20234:05PMBusiness WireDeciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      08/09/20237:09AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      08/09/20237:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      08/09/20237:00AMBusiness WireDeciphera Pharmaceuticals Announces Second Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      08/03/20234:20PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      08/03/20234:15PMBusiness WireDeciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific OfficerNASDAQ:DCPHDeciphera Pharmaceuticals Inc
      08/02/20237:00AMBusiness WireDeciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/23/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/23/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/23/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/23/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/23/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/23/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/23/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/23/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/22/20234:06PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      06/21/20234:06PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:DCPHDeciphera Pharmaceuticals Inc
      05/25/20235:00PMBusiness WireDeciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual MeetingNASDAQ:DCPHDeciphera Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:DCPH